English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, October 14, 2020
華領醫藥宣佈獲得《藥品生產許可證》
Hua Medicine Announces the Drug Manufacturing Permit Granted for Dorzagliatin
Monday, August 17, 2020
拜耳与华领医药宣布在糖尿病领域建立战略合作 双方就处于临床试验阶段的首创糖尿病治疗药物dorzagliatin在中国达成商业合作协议
拜耳與華領醫藥宣佈在糖尿病領域建立戰略合作 雙方就處於臨床試驗階段的首創糖尿病治療藥物dorzagliatin在中國達成商業合作協議
Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China
Wednesday, July 1, 2020
华领医药宣布Dorzagliatin与二甲双胍联合用药III期注册临床研究24周核心研究取得正面结果
華領醫藥宣佈Dorzagliatin與二甲雙胍聯合用藥III期註冊臨床研究24週核心研究取得正面結果
Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin
Thursday, June 18, 2020
华领医药成功完成Dorzagliatin单药治疗III期临床试验SEED研究(HMM0301)
華領醫藥成功完成Dorzagliatin單藥治療III期臨床試驗SEED研究(HMM0301)

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575